Treatments

Ivermectin: Still on a Losing Streak as COVID-19 Treatment | MedPage Today

WASHINGTON -- There were no differences in relief from mild-to-moderate COVID-19 symptoms for patients on ivermectin versus placebo, according to the ongoing ACTIV-6 trial.

Among >1,000 vaccinated and unvaccinated patients, the median time to recovery was 12 days for those in the ivermectin group and 13 days in the placebo group, reported Matthew McCarthy, MD, of Weill Cornell Medicine in New York City, at IDWeek.

As a result, the hazard ratio for improvement in time to recovery was 1.07 (95% credible interval 0.96-1.17, posterior P=0.91), McCarthy and colleagues stated in JAMA, where the results were simultaneously published.

...

Omicron subvariants pose a new threat to people with immune deficiencies (nbcnews.com)

New versions of the omicron virus show resistance to the antibody drugs many need for extra protection against Covid.

---

People with compromised immune systems face a new winter of discontent as the ever-mutating omicron virus threatens to outrun the preventive monoclonal antibody cocktail that hundreds of thousands of them have relied upon for extra protection against Covid.

Pfizer says COVID-19 vaccine will cost $110-$130 per dose Pfizer will charge $110 to $130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots, but the drugmaker says it expects many people will continue receiving it for free. AP NEWS

...

Pfizer executives said the commercial pricing for adult doses could start early next year, depending on when the government phases out its program of buying and distributing the shots.

Panel votes to add COVID shots to recommended vaccinations NEW YORK (AP) — COVID-19 shots should be added to the lists of recommended vaccinations for kids and adults, a panel of U.S. vaccine experts said Thursday. The panel's unanimous decision has no immediate effect — COVID-19 shots already are recommended for virtually all Americans. AP NEWS

...